AEYE Health Study Validates AI for Diabetic Eye Screening
New York, August 4, 2026 AEYE Health has announced the publication of a real-world clinical study in the British...
endocrinology
Advertisement
BridgeBio Announces FDA Acceptance of Encaleret NDA for ADH1
PALO ALTO, Calif., July 22, 2026 BridgeBio has reached a significant regulatory milestone after the U.S. Food and Drug...
Camurus NDA Resubmission for CAM2029 Accepted by FDA
LUND, Sweden, July 17, 2026 Camurus announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Rhythm Publishes Phase 3 IMCIVREE Data in NEJM
BOSTON, Mass., July 8, 2026 Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the...
Neurocrine Initiates Phase 2 Trial of Crinecerfont in Children Under 4 with Classic CAH
SAN DIEGO, July 1, 2026 Neurocrine Biosciences announced the initiation of a Phase 2 clinical trial evaluating crinecerfont (CRENESSITY®)...
Advertisements
Cumulus Advances Alzheimer’s Research with NeuLogiq Platform
BELFAST, Northern Ireland, June 30, 2026 Cumulus Neuroscience has announced the publication of new findings in Frontiers in Digital...
STARMED Becomes First to Gain FDA Clearance for Thyroid RFA
LOS ANGELES, Calif., June 30, 2026 STARMED America has achieved a historic milestone in thyroid disease treatment after receiving...
Corcept Resubmits Relacorilant NDA for Cushing’s Syndrome to FDA
REDWOOD CITY, Calif., June 17, 2026 Corcept Therapeutics Incorporated announced the resubmission of its New Drug Application (NDA) to...
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Advertisement
